Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Background

Upadacitinib, a Janus kinase (JAK) inhibitor used in rheumatoid arthritis treatment, has prompted safety concerns due to potential cardiovascular adverse events. However, current evidence does not provide a definitive conclusion.

Methods

We conducted a comprehensive systematic review of the literature up until March 15, 2024, utilizing databases like PubMed/Medline, Embase, and Cochrane CENTRAL. A meta-analysis approach was used to derive pooled odds ratios (OR) along with their 95% confidence intervals (CI) to assess the cardiovascular risk associated with upadacitinib. Publication bias was evaluated using Begg's and Egger's tests.

Results

Our meta-analysis included six studies with a total of 4,202 participants. For the 15 mg dosage of Upadacitinib, the pooled OR was 1.20 (95% CI: 0.3-4.3), indicating a nominal, non-significant increase in the risk of cardiovascular adverse events. Analysis of the 30 mg dosage presented a pooled OR of 2.37 (95% CI: 0.6-9.1), pointing to a higher, yet statistically insignificant, potential risk. The absence of publication bias was confirmed through Begg's and Egger’s tests.

Conclusion

The analysis suggests a potential heightened cardiovascular risk associated with Upadacitinib, more so with the 30 mg dosage. Nevertheless, the lack of statistical significance and the wide confidence intervals necessitate a prudent approach to these findings. Tailored treatment strategies, rigorous monitoring, and further empirical studies are crucial for refining the safety profile of upadacitinib and ensuring optimal patient outcomes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971342481241101061013
2024-11-07
2025-11-28

  • From This Site

    /content/journals/crr/10.2174/0115733971342481241101061013
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RaduA.F. BungauS.G. Management of rheumatoid arthritis: An overview.Cells20211011285710.3390/cells10112857
     [Google Scholar]
  2. SchererH.U. HäuplT. BurmesterG.R. The etiology of rheumatoid arthritis.J. Autoimmun.202011010240010.1016/j.jaut.2019.102400
     [Google Scholar]
  3. WeyandC.M. GoronzyJ.J. The immunology of rheumatoid arthritis.Nat. Immunol.2021221101810.1038/s41590‑020‑00816‑x
     [Google Scholar]
  4. AlmutairiK. NossentJ. PreenD. KeenH. InderjeethC. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review.Rheumatol. Int.202141586387710.1007/s00296‑020‑04731‑0
     [Google Scholar]
  5. SafiriS. KolahiA.A. HoyD. SmithE. BettampadiD. MansourniaM.A. HashianiA.A. AsgarabadA.A. LakehM.M. QorbaniM. CollinsG. WoolfA.D. MarchL. CrossM. Global, regional and national burden of rheumatoid arthritis 1990–2017: A systematic analysis of the global burden of disease study 2017.Ann. Rheum. Dis.201978111463147110.1136/annrheumdis‑2019‑215920
     [Google Scholar]
  6. YamaokaK. Janus kinase inhibitors for rheumatoid arthritis.Curr. Opin. Chem. Biol.201632293310.1016/j.cbpa.2016.03.006
     [Google Scholar]
  7. O’SheaJ.J. KontziasA. YamaokaK. TanakaY. LaurenceA. Janus kinase inhibitors in autoimmune diseases.Ann. Rheum. Dis.2013722ii111ii11510.1136/annrheumdis‑2012‑202576
     [Google Scholar]
  8. LangbourC. ReneJ. GoupilleP. AlegriaC.G. Efficacy of Janus kinase inhibitors in rheumatoid arthritis.Inflamm. Res.20237251121113210.1007/s00011‑023‑01717‑z
     [Google Scholar]
  9. LeeSW, Kim S, Jeon HJ, Min HK. Incidence if autoimmune inflammatory rheumatic diseases after COVID‐19 in South Korea: A nationwide cohort study based on health insurance data.Intern J. Rheu Dis.2024276
     [Google Scholar]
  10. ParkJ. LeeM. LeeH. KimH.J. KwonR. YangH. LeeS.W. KimS. RahmatiM. KoyanagiA. SmithL. KimM.S. JacobL. SánchezL.G.F. ElenaD. ShinJ.I. RheeS.Y. YooM.C. YonD.K. National trends in rheumatoid arthritis and osteoarthritis prevalence in South Korea, 1998–2021.Sci. Rep.20231311952810.1038/s41598‑023‑46279‑6
     [Google Scholar]
  11. WuD. JinY. XingY. AbateM.D. AbbasianM. KangevariA.M. KangevariA.Z. AllahA.F. AbdelmassehM. AbdollahifarM-A. AbdulahD.M. AbediA. AbediV. AbidiH. AboagyeR.G. AbolhassaniH. AbuabaraK. AbyadehM. AddoI.Y. AdenijiK.N. AdepojuA.V. AdesinaM.A. AdnaniS.Q.E. AfaridehM. AghamiriS. AgodiA. AgrawalA. ArriagadaA.C.E. AhmadA. AhmadD. AhmadS. AhmadS. AhmadiA. AhmedA. AhmedA. AithalaJ.P. AjadiA.A. AjamiM. KhiaviA.M. AlahdabF. AlBatainehM.T. AlemiS. GheethiS.A.A.A. AliL. AlifS.M. AlmazanJ.U. AlmustanyirS. AlqahtaniJ.S. AlqasmiI. AltafK.I.U. GuzmanA.N. ZakzukA.N.J. WorafiA.Y.M. AlyH. AmaniR. AmuH. AmusaG.A. AndreiC.L. AnsarA. AnsariniyaH. AnyasodorA.E. ArablooJ. ArefnezhadR. ArulappanJ. JafarabadiA.M. AshrafT. AtataJ.A. AthariS.S. AtlawD. AtoutW.M.M. AujayebA. AwanA.T. AyatollahiH. AzadnajafabadS. AzzamA.Y. BadawiA. BadiyeA.D. BagheriehS. BaigA.A. BantieB.B. BarchittaM. BardhanM. ColloB.S.L. AdesiB.F. BatraK. BayileyegnN.S. BehnoushA.H. BelgaumiU.I. BemanalizadehM. BensenorI.M. BeyeneK.A. BhagavathulaA.S. BhardwajP. BhaskarS. BhatA.N. BitarafS. BitraV.R. BoloorA. BoraK. BotelhoJ.S. BuchbinderR. CalinaD. CámeraL.A. CarvalhoA.F. ChanK.J.S. ChattuV.K. AbebeE.C. ChichagiF. ChoiS. ChouT-C. ChuD-T. CoberlyK. CostaV.M. CoutoR.A.S. MartinsC.N. DadrasO. DaiX. DamianiG. DascaluA.M. DashtiM. DebelaS.A. DellavalleR.P. DemetriadesA.K. DemlashA.A. DengX. DesaiH.D. DesaiR. DewanR.S.M. DeyS. DharmaratneS.D. DiazD. DibasM. OliveiraD.R.J. DiressM. DoT.C. DoanD.K. DodangehM. DodangehM. DongarwarD. DubeJ. DziedzicA.M. DraE.A. EdinurH.A. EissazadeN. EkholuenetaleM. EkundayoT.C. ElemamN.M. ElhadiM. ElmehrathA.O. ElmeligyA.O.A. EmamverdiM. EmetoT.I. EsayasH.L. EshetuH.B. EtaeeF. FagbamigbeA.F. FaghaniS. FakhradiyevI.R. FatehizadehA. FathiM. FeizkhahA. FekaduG. FereidouniM. FereshtehnejadS-M. FernandesJ.C. FerraraP. FetensaG. FilipI. FischerF. ForoutanB. ForoutanM. FukumotoT. GanesanB. GemedaB.B.N. GhamariS-H. GhasemiM.R. GholamalizadehM. GillT.K. GillumR.F. GoldustM. GolechhaM. GoleijP. GolinelliD. GoudarziH. GuanS-Y. GuoY. GuptaB. GuptaV.B. GuptaV.K. HaddadiR. HadiN.R. HalwaniR. HaqueS. HasanI. HashempourR. HassanA. HassanT.S. HassanzadehS. HassenM.B. HauboldJ. HayatK. HeidariG. HeidariM. SoureshjaniH.R. HerteliuC. HessamiK. HezamK. HiraikeY. HollaR. HosseiniM-S. HuynhH-H. HwangB-F. IbitoyeS.E. IlicI.M. IlicM.D. IranmehrA. IravanpourF. IsmailN.E. IwagamiM. IwuC.C.D. JacobL. JafariniaM. JafarzadehA. JahankhaniK. JahramiH. JakovljevicM. JamshidiE. JaniC.T. JanodiaM.D. JayapalS.K. JayaramS. JeganathanJ. JonasJ.B. JosephA. JosephN. JoshuaC.E. VaishaliK. KaambwaB. KabirA. KabirZ. KadashettiV. KaliyadanF. KalrooziF. KamalV.K. KandelA. KandelH. KanungoS. KaramiJ. KarayeI.M. KarimiH. KasraeiH. KazemianS. KebedeS.A. AraniK.L. KeykhaeiM. KhaderY.S. KhajuriaH. KhamesipourF. KhanE.A. KhanI.A. KhanM. KhanM.J. KhanM.A.B. KhanM.A. KhatatbehH. KhatatbehM.M. KhateriS. KashaniK.H.R. KimM.S. KisaA. KisaS. KohH.Y. KolkhirP. KorzhO. KotnisA.L. KoulP.A. KoyanagiA. KrishanK. KuddusM. KulkarniV.V. KumarN. KunduS. KurmiO.P. VecchiaL.C. LahariyaC. LaksonoT. LámJ. LatiefK. LauriolaP. LawalB.K. LeT.T.T. Bich LeT.T. LeeM. LeeS.W. LeeW-C. LeeY.H. LenziJ. LeviM. LiW. LigadeV.S. LimS.S. LiuG. LiuX. LlanajE. LoC-H. MachadoV.S. MaghazachiA.A. MahmoudM.A. MaiT.A. MajeedA. SanayeP.M. MakramO.M. RadE.M. MalhotraK. MalikA.A. MalikI. MallhiT.H. MaltaD.C. MansourniaM.A. MantovaniL.G. MartorellM. MasoudiS. MasoumiS.Z. MathangasingheY. MathewsE. MathioudakisA.G. MaugeriA. MayeliM. MedinaC.J.R. MelesG.G. MendesJ.J. MenezesR.G. MestrovicT. MichalekI.M. SáM.G.N.D.A.C. MihretieE.T. Nhat MinhL.H. MirfakhraieR. MirrakhimovE.M. MisganawA. MohamadkhaniA. MohamedN.S. MohammadiF. MohammadiS. MohammedS. MohammedS. MohanS. MohseniA. MokdadA.H. MomtazmaneshS. MonastaL. MoniM.A. MoniruzzamanM. MoradiY. MorovatdarN. MostafaviE. MousaviP. MukoroG.D. MulitaA. MuluG.B. ZamoraM.E. MusaigwaF. MustafaG. MuthuS. NainuF. NangiaV. SwamyS.N. NattoZ.S. NavarajP. NayakB.P. PanjakiN.A. NegashH. NematollahiM.H. NguyenD.H. NguyenH.H.T. NguyenH.Q. NguyenP.T. NguyenV.T. NiaziR.K. NikolouzakisT.K. NnyanziL.A. NoreenM. NzoputamC.I. NzoputamO.J. OanceaB. OhI-H. AliabadO.H. OkonjiO.C. OkwuteP.G. OlagunjuA.T. OlatubiM.I. OlufadewaI.I. OrdakM. OtstavnovN. OwolabiM.O. MaheshP.A. PadubidriJ.R. PakA. PakzadR. PalladinoR. PanaA. PantazopoulosI. PapadopoulouP. PardhanS. ParthasarathiA. PashaeiA. PatelJ. PathanA.R. PatilS. PaudelU. PawarS. PedersiniP. PensatoU. PereiraD.M. PereiraJ. PereiraM.O. PereiraR.B. PeresM.F.P. PerianayagamA. PernaS. PetcuI-R. PezeshkiP.S. PhamH.T. PhilipA.K. PiradovM.A. PodderI. PodderV. PoddigheD. PratesS.E.J. QatteaI. RadfarA. RaeeP. RafieiA. RaggiA. RahimF. RahimiM. RahimifardM. MovagharR.V. RahmanM.O. RahmanU.M.H. RahmanM. RahmanM.A. RahmaniA.M. RahmaniM. RahmaniS. RahmanianV. RamasubramaniP. RancicN. RaoI.R. RashediS. RashidA.M. RavikumarN. RawafS. RedwanM.E.M. RezaeiN. RezaeiN. RezaeiN. RezaeianM. RibeiroD. RodriguesM. RodriguezB.J.A. RoeverL. RodríguezR.E. SaadA.M.A. SaddikB. SadeghianS. SaeedU. SafaryA. SafdarianM. SafiS.Z. SaghazadehA. SagoeD. AskariS.F.S. AskariS.N.S. SahebkarA. SahooH. SahraianM.A. SajidM.R. SakhamuriS. SakshaugJ.W. SalehM.A. SalehiL. SalehiS. FarrokhiA.S. SamadzadehS. SamargandyS. SamieefarN. SamyA.M. SanadgolN. SanjeevR.K. SawhneyM. SayaG.K. SchuermansA. SenthilkumaranS. SepanlouS.G. SethiY. ShafieM. ShahH. ShahidI. ShahidS. ShaikhM.A. SharfaeiS. SharmaM. ShayanM. ShehataH.S. SheikhA. ShettyJ.K. ShinJ.I. ShirkoohiR. ShitayeN.A. ShivakumarK.M. ShivarovV. ShobeiriP. SiabaniS. SibhatM.M. SiddigE.E. SimpsonC.R. SinaeiE. SinghH. SinghI. SinghJ.A. SinghP. SinghS. SirajM.S. SohagA.M.A. SolankiR. SolikhahS. SolomonY. ZangbarS.M.S. SunJ. SzetoM.D. SeisdedosT.R. TabatabaeiS.M. TabishM. TaheriE. TahvildariA. TalaatI.M. TamuziL.J.J.L. TanK-K. TatN.Y. OliaeeR.T. TavasolA. TemsahM-H. ThangarajuP. TharwatS. TibebuN.S. TicoaluV.J.H. TillawiT. TiruyeT.Y. TiyuriA. PaloneT.M.R. TripathiM. TsegayG.M. TualekaA.R. TyS.S. UbahC.S. UllahS. UllahS. UmairM. UmakanthanS. UpadhyayE. VahabiS.M. VaithinathanA.G. TahbazS.V. ValizadehR. VarthyaS.B. VasankariT.J. VenketasubramanianN. VerrasG-I. VillafañeJ.H. VlassovV. VoD.C. WaheedY. WarisA. WelegebrialB.G. WestermanR. WickramasingheD.P. WickramasingheN.D. WillekensB. WoldegeorgisB.Z. WoldemariamM. XiaoH. YadaD.Y. YahyaG. YangL. YazdanpanahF. YonD.K. YonemotoN. YouY. ZahirM. ZaidiS.S. ZangiabadianM. ZareI. ZeineddineM.A. ZemedikunD.T. ZeruN.G. ZhangC. ZhaoH. ZhongC. ZielińskaM. ZoladlM. ZumlaA. GuoC. TamL. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: Findings from the global burden of disease study 2019.E. Clin. Med.20236410219310.1016/j.eclinm.2023.102193
     [Google Scholar]
  12. ScottI.C. HiderS.L. ScottD.L. Thromboembolism with janus kinase (JAK) inhibitors for rheumatoid arthritis: How real is the risk?Drug Saf.201841764565310.1007/s40264‑018‑0651‑5
     [Google Scholar]
  13. KotylaP.J. IslamM.A. EngelmannM. Clinical aspects of janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis.Int. J. Mol. Sci.20202119739010.3390/ijms21197390
     [Google Scholar]
  14. MisraD.P. PandeG. AgarwalV. Cardiovascular risks associated with Janus kinase inhibitors: Peering outside the black box.Clin. Rheumatol.202342262163210.1007/s10067‑022‑06415‑5
     [Google Scholar]
  15. NashP. LimI. MarabaniM. A comparison of janus kinase inhibitor safety in rheumatoid arthritis.Int. J. Rheum. Dis.202124S131410.1111/1756‑185X.14127
     [Google Scholar]
  16. AtzeniF. CarrioR.J. PopaC.D. NurmohamedM.T. SzűcsG. SzekaneczZ. Cardiovascular effects of approved drugs for rheumatoid arthritis.Nat. Rev. Rheumatol.202117527029010.1038/s41584‑021‑00593‑3
     [Google Scholar]
  17. YangJM, Jung SY, Kim MS. Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: A World Health Organization pharmacovigilance study.Ophthalmology202513216278
     [Google Scholar]
  18. CrowsonC.S, Liao KP, Davis III JM Rheumatoid arthritis and cardiovascular disease.American Hear. J.2013166462262810.1016/j.ahj.2013.07.010
     [Google Scholar]
  19. FleischmannR. CurtisJ.R. SchoemanC.C. MyslerE. YamaokaK. RichezC. PalacH. DilleyD. LiuJ. StrengholtS. BurmesterG. Safety profile of upadacitinib in patients at risk of cardiovascular disease: Integrated post hoc analysis of the select phase III rheumatoid arthritis clinical programme.Ann. Rheum. Dis.20238291130114110.1136/ard‑2023‑223916
     [Google Scholar]
  20. FleischmannR. MyslerE. BessetteL. PeterfyC.G. DurezP. TanakaY. SwierkotJ. KhanN. BuX. LiY. SongI-H. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: Results through 3 years from the select-compare study.RMD Open202281e00201210.1136/rmdopen‑2021‑002012
     [Google Scholar]
  21. CohenS.B. VollenhovenV.R.F. WinthropK.L. ZerbiniC.A.F. TanakaY. BessetteL. ZhangY. KhanN. HendricksonB. EnejosaJ.V. BurmesterG.R. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the select phase III clinical programme.Ann. Rheum. Dis.202180330431110.1136/annrheumdis‑2020‑218510
     [Google Scholar]
  22. PageM.J. McKenzieJ.E. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. WilsonM.E. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. MoherD. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.Int. J. Surg.20218810590610.1016/j.ijsu.2021.105906
     [Google Scholar]
  23. AndersonJ. CaplanL. YazdanyJ. RobbinsM.L. NeogiT. MichaudK. SaagK.G. O’dellJ.R. KaziS. Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice.Arthritis Care Res.201264564064710.1002/acr.21649
     [Google Scholar]
  24. BurmesterG.R. KremerJ.M. BoschV.D.F. KivitzA. BessetteL. LiY. ZhouY. OthmanA.A. PanganA.L. CampH.S. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial.Lancet2018391101392503251210.1016/S0140‑6736(18)31115‑2
     [Google Scholar]
  25. GenoveseM.C. FleischmannR. CombeB. HallS. RothR.A. ZhangY. ZhouY. MohamedM-E.F. MeerweinS. PanganA.L. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial.Lancet2018391101392513252410.1016/S0140‑6736(18)31116‑4
     [Google Scholar]
  26. FleischmannR. PanganA.L. SongI-H. MyslerE. BessetteL. PeterfyC. DurezP. OstorA.J. LiY. ZhouY. OthmanA.A. GenoveseM.C. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III, double-blind, randomized controlled trial.Arthritis Rheumatol.201971111788180010.1002/art.41032
     [Google Scholar]
  27. SmolenJ.S. PanganA.L. EmeryP. RigbyW. TanakaY. VargasJ.I. ZhangY. DamjanovN. FriedmanA. OthmanA.A. CampH.S. CohenS. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study.Lancet2019393101882303231110.1016/S0140‑6736(19)30419‑2
     [Google Scholar]
  28. VollenhovenV.R. TakeuchiT. PanganA.L. FriedmanA. MohamedM-E.F. ChenS. RischmuellerM. BlancoR. XavierR.M. StrandV. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): A multicenter, multi-country, randomized, double-blind, active comparator–controlled trial.Arthritis Rheumatol.202072101607162010.1002/art.41384
     [Google Scholar]
  29. KamedaH. TakeuchiT. YamaokaK. OribeM. KawanoM. ZhouY. OthmanA.A. PanganA.L. KitamuraS. MeerweinS. TanakaY. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): A placebo-controlled phase IIb/III study.Rheumatology202059113303331310.1093/rheumatology/keaa084
     [Google Scholar]
  30. VanMilV.D.H.A.H.M. CessieL.S. DongenV.H. BreedveldF.C. ToesR.E.M. HuizingaT.W.J. A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions.Arthritis Rheum.200756243344010.1002/art.22380
     [Google Scholar]
  31. VollenhovenV.R. Treat-to-target in rheumatoid arthritis — Are we there yet?Nat. Rev. Rheumatol.201915318018610.1038/s41584‑019‑0170‑5
     [Google Scholar]
  32. FraenkelL, Bathon JM, England BR. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis.Arthritis Rheumatol.20217371108112310.1002/art.41752
     [Google Scholar]
  33. DaneseS. VermeireS. ZhouW. PanganA.L. SiffledeenJ. GreenbloomS. HébuterneX. D’HaensG. NakaseH. PanésJ. HigginsP.D.R. JuilleratP. LindsayJ.O. LoftusE.V.Jr SandbornW.J. ReinischW. ChenM-H. GonzalezS.Y. HuangB. XieW. LiuJ. WeinreichM.A. PanaccioneR. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials.Lancet2022399103412113212810.1016/S0140‑6736(22)00581‑5
     [Google Scholar]
  34. SandbornWJ, Ghosh S, Panes J. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis.Gastroenterology202015882139214910.1053/j.gastro.2020.02.030
     [Google Scholar]
  35. BobadillaP.A.V. StodtmannS. EckertD. ZhouW. LiuW. MohamedM-E.F. Upadacitinib population pharmacokinetics and exposure-response relationships in ulcerative colitis patients.Clin. Pharmacokinet.202362110111210.1007/s40262‑022‑01191‑6
     [Google Scholar]
  36. DougadosM. SoubrierM. AntunezA. BalintP. BalsaA. BuchM.H. CasadoG. DetertJ. ZorkanyE.B. EmeryP. HassouniH.N. HarigaiM. LuoS-F. KuruczR. MacielG. MolaE.M. MontecuccoC.M. McInnesI. RadnerH. SmolenJ.S. SongY-W. VonkemanH.E. WinthropK. KayJ. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA).Ann. Rheum. Dis.2014731626810.1136/annrheumdis‑2013‑204223
     [Google Scholar]
  37. RielV.P. AltenR. CombeB. AbdulganievaD. BousquetP. CourtenayM. CurialeC. CentenoG.A. HaugebergG. LeebB. PuolakkaK. RavelliA. RintelenB. PuttiniS.P. Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools.RMD Open201622e00030210.1136/rmdopen‑2016‑000302
     [Google Scholar]
  38. KhusainovaM.A, Vakhidov JJ, Khayitov SM Cardiac arrhythmias in patients with rheumatoid arthritis.Sci. Educ.202342130137
     [Google Scholar]
  39. DhillonN. LiangK. Prevention of stroke in rheumatoid arthritis.Curr. Treat. Options Neurol.20151773110.1007/s11940‑015‑0356‑3
     [Google Scholar]
/content/journals/crr/10.2174/0115733971342481241101061013
Loading
Upadacitinib and Cardiovascular Adverse Events in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Curr. Rheumatol. Rev. 21, 604 (2025); https://doi.org/10.2174/0115733971342481241101061013
/content/journals/crr/10.2174/0115733971342481241101061013
/content/journals/crr/10.2174/0115733971342481241101061013
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): cardiovascular adverse events; Janus kinase inhibitor; meta-analysis, publication bias; rheumatoid arthritis; Upadacitinib

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test